oncology focus ImClone Systems, a Lilly subsidiary, specializes in oncology with a portfolio of targeted biologic treatments, suggesting sales opportunities with oncology centers, contract research organizations supporting cancer trials, and payers seeking novel cancer therapeutics.

biotech scale With 201-500 employees and a fully integrated global biopharmaceutical model, there is potential for collaboration across clinical development, manufacturing partnerships, and regional market access initiatives to expand leverage with mid-sized biotechs, CROs, and distributors.

mature ownership As a wholly owned subsidiary of Eli Lilly since 2008, leverage Lilly’s broader portfolio, sales channels, and resource network to explore co-promotion, licensing, or strategic partnerships for complementary oncology programs.

revenue signal Reported revenue in the mid hundreds of millions indicates a scalable commercial footprint; sales opportunities could focus on tiered market access strategies, payer negotiation support, and value-based pricing discussions with oncology practices.

research momentum Public mentions of monoclonal antibody development for cancer point to ongoing R&D activity; business development can target collaboration on new biologics, companion diagnostics, and real-world evidence initiatives to strengthen market adoption.